Nucleoside derivatives for treating Hepatitis C virus infection

Details Nucleoside derivatives for treating Hepatitis C virus infection Nucleoside derivatives for treating Hepatitis C virus infection

2006-07-24

2008-10-07

Lewis, Patrick T. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S026230, C536S026260, C536S026700, C536S027200

Reexamination Certificate

active

07432248

ABSTRACT:
Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows:wherein W, W1, W2, Y, R1, Z, Y′ and R are as defined herein.

REFERENCES:
patent: 5430027 (1995-07-01), Knutsen et al.
patent: 5681941 (1997-10-01), Cook et al.
patent: 5763167 (1998-06-01), Conrad
patent: 5977332 (1999-11-01), Martin
patent: 6211154 (2001-04-01), Scarborough et al.
patent: 6475985 (2002-11-01), Wagner et al.
patent: 6500946 (2002-12-01), Takamatsu et al.
patent: 6586413 (2003-07-01), Liang et al.
patent: 6660721 (2003-12-01), Devos et al.
patent: 6703394 (2004-03-01), Engelhardt et al.
patent: 6777395 (2004-08-01), Bhat et al.
patent: 7094768 (2006-08-01), Roberts et al.
patent: 2003/0130226 (2003-07-01), Loakes et al.
patent: 2007/0015905 (2007-01-01), LaColla et al.
patent: 2007/0032449 (2007-02-01), LaColla et al.
patent: 1117669 (2000-04-01), None
patent: WO/94/18215 (1994-08-01), None
patent: WO/95/07919 (1995-03-01), None
patent: WO 02/057287 (2002-07-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO/03/061576 (2003-07-01), None
patent: WO03/061576 (2003-07-01), None
patent: WO 03/072757 (2003-09-01), None
patent: WO/2004/028481 (2004-04-01), None
patent: WO/2004/065398 (2004-08-01), None
Beigelman et al. “New Syntheses of 2′-C-methynucleosides Starting from D-Glucose and D-Ribose”Carbo. Research, 166:219-232 (1987).
Hinshaw, et al. “Pyrrolopyrimidine nucleosides. IV. Synthesis of certain 4, 5-disubstituted-7-(.beta.-D-ribofuranosy 1)pyrrolo[2,3-d]pyrimidine nucleoside antibiotics”J. of Heterocyclic Chemistry6(2):215-221 CODEN: JHTCAD; ISSN: 0022-152X, (1969) XP002388343.
Hinshaw, et al. “Pyrrolopyrimidien nucleosides. X. Synthesis of 4,5-disubstituted 7-(.beta.-D-ribofuranosyl)pyrrolo[2,3-d]py rimidines related to toyocamycin and sangivamycin”J. of the Chemical Society, Perkin Transactions: Organic and Bio-Organic Chemistry(1972-1999), (13), 1248-53 CODEN: JCPRB4; ISSN: 0300-922X (1975), XP009068854.
Ding, et al. “Synthesis of 2′-beta-C-methyl toyocamycin and sangivamycin analogues as potential HCV inhibitors”Bioorganic&Medicinal Chemistry Letters, Oxford, GB 15(3):725-727 (Feb. 1, 2005).
Bowler et al., “New Adenosine A3 Ligands Controlling Cytokines,”Drug Development Research, 37, 173 (bottom of column 2) (Mar. 1996).
Jacobson et al., “Recent Developments in selective Agonists and Antagonists Acting at Purine and Pyrimidine Receptors,”Drug Development Research, 39(3-4), 289-300 (1996).

Affiliated with

Also associated with

Rating

Nucleoside derivatives for treating Hepatitis C virus infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleoside derivatives for treating Hepatitis C virus infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleoside derivatives for treating Hepatitis C virus infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4007137